Takeda Pharmaceutical annual r&d spending
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Takeda Pharmaceutical R&D Spending Growth & History (TAK)
Takeda Pharmaceutical's r&d spending was ¥675.92B for fiscal 2026.
View full Takeda Pharmaceutical company overviewTakeda Pharmaceutical annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | ¥675.92B | −¥54.30B | −7.44% |
| 2025 | 2025-03-31 | ¥730.23B | ¥303.0M | +0.04% |
| 2024 | 2024-03-31 | ¥729.92B | ¥96.60B | +15.25% |
| 2023 | 2023-03-31 | ¥633.33B | ¥107.24B | +20.38% |
| 2022 | 2022-03-31 | ¥526.09B | ¥70.25B | +15.41% |
| 2021 | 2021-03-31 | ¥455.83B | −¥36.55B | −7.42% |
| 2020 | 2020-03-31 | ¥492.38B | ¥124.08B | +33.69% |
| 2019 | 2019-03-31 | ¥368.30B | ¥42.86B | +13.17% |
| 2018 | 2018-03-31 | ¥325.44B | ¥13.14B | +4.21% |
| 2017 | 2017-03-31 | ¥312.30B | — | — |
Takeda Pharmaceutical quarterly r&d spending
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | ¥167.40B | ¥23.50B | +16.33% |
| Q4 2026 | 2026-03-31 | ¥195.32B | — | — |
| Q3 2026 | 2025-12-31 | ¥175.23B | — | — |
| Q2 2026 | 2025-09-30 | ¥161.48B | — | — |
| Q1 2026 | 2025-06-30 | ¥143.89B | — | — |
Takeda Pharmaceutical r&d spending trends
Over the last five fiscal years, Takeda Pharmaceutical's r&d spending increased from ¥455.83B to ¥675.92B, a change of ¥220.09B. The latest reported quarter, Q1 2027, shows ¥167.40B.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Takeda Pharmaceutical source filings ↗